After two years of intensive renovation work, the new location of Charité BIH Innovation (CBI) - the joint technology transfer of Charité and BIH - has opened on October 12. Covering a total of 2,500 m2 spread over four floors, the modern, expanded…
Reverse Clinical Engineering® is now available to oncologists and cancer patients in Saudi Arabia, the Middle East, and North Africa. ASC Oncology proudly announces new partnership with Tamer Group.
Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix…
Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial.
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors
TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01
IMAG1NE…
Berlin, Germany and Stockholm, Sweden, October 20, 2022:
FyoniBio, a CDO expert specialized in tailored cell line development and Strike Pharma, whose proprietary
Adaptable Drug Affinity Conjugate (ADAC) technology enables development of …
The term “Long COVID” first emerged in the social media. Numerous affected individuals have reported in the social media about their various, long-lasting health limitations after SARS-CoV-2 infection. In the Berlin-Brandenburg metropolitan region,…
pharmtrace, a German, Berlin based provider of Independent expertise for nuclear medicine, diagnostics, and drug development clinical trials has established a representative office in Philadelphia. pharmtrace is currently enjoying increasing…
NUVISAN’s integrated drug discovery expertise leveraged in a grant from the Bill & Melinda Gates Foundation
To prevent diseases from occurring in the first place, it is important to identify those individuals who are at particularly high risk as early as possible. Yet current screening methods are often costly and focus only on one disease at a time.…
